CMD in Stockholm to show steps foward with mesdopetam
Yesterday IRLAB Therapeutics hosted its 2023 capital markets day (CMD). IRLAB's Management team gave a nice overview of the company, including a detailed overview of the Ph 2b results in PD-LIDs with mesdopetam. The CMD also hosted a presentation from KOL Karl Kieburtz, MD, MHD, Professor in Neurology, where he outlined the potential regulatory steps forward regarding future Ph 3 development for mesdopetam.
Aktuellt
SENASTE
